Dabrafenib + Trametinib After Radiation for Brain Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial studies how well dabrafenib and trametinib work after radiation therapy in children and young adults with a specific type of brain tumor. These drugs help stop tumor growth by blocking signals that tell the cells to multiply. Dabrafenib has been developed and tested extensively for a specific type of skin cancer, showing effectiveness both alone and when used with trametinib.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, if you have a seizure disorder, you can participate if your seizures are well controlled with non-enzyme inducing anticonvulsants. It's best to discuss your specific medications with the trial team.
Do I need to stop my current medications for this trial?
The trial protocol does not specify if you need to stop taking your current medications. However, it mentions that patients with a seizure disorder can participate if their seizures are well controlled on non-enzyme inducing anticonvulsants, which suggests some medications may be allowed. It's best to discuss your specific medications with the trial team.
What safety data exists for Dabrafenib + Trametinib after radiation for brain cancer?
The provided research does not directly address the safety data for Dabrafenib + Trametinib after radiation for brain cancer. However, it includes studies on the safety and toxicity of various radiotherapy techniques, such as stereotactic radiotherapy (SRT), intensity-modulated radiotherapy (IMRT), and image-guided radiotherapy (IGRT), in different cancer treatments. These studies highlight the importance of advanced radiotherapy techniques in reducing toxicity, but specific safety data for the combination of Dabrafenib and Trametinib with radiation therapy for brain cancer is not covered in the provided abstracts.12345
Is the combination of Dabrafenib, Trametinib, and various forms of radiotherapy generally safe for humans?
Research shows that advanced radiotherapy techniques like intensity-modulated radiotherapy (IMRT) and stereotactic body radiation therapy (SBRT) are generally safe, with some risk of gastrointestinal and genitourinary side effects. These techniques have been used safely in treating various cancers, including prostate and cervical cancer.12345
Is Radiation Therapy a promising treatment for brain cancer when used with Dabrafenib and Trametinib?
How is the treatment of Dabrafenib + Trametinib after radiation therapy unique for brain cancer?
This treatment combines radiation therapy with two drugs, Dabrafenib and Trametinib, which target specific mutations (BRAF V600E) in brain tumors. This approach is unique because it combines targeted drug therapy with radiation, potentially enhancing effectiveness against certain brain cancers with specific genetic mutations.678910
What data supports the idea that Dabrafenib + Trametinib After Radiation for Brain Cancer is an effective treatment?
The available research does not provide specific data on the effectiveness of Dabrafenib + Trametinib after radiation for brain cancer. The studies focus on different radiotherapy techniques and their advancements, but they do not directly address the combination of Dabrafenib and Trametinib with radiation for brain cancer. Therefore, we cannot conclude its effectiveness based on the provided information.211121314
What data supports the effectiveness of the treatment Dabrafenib + Trametinib after radiation for brain cancer?
Research shows that advanced radiotherapy techniques like intensity-modulated radiotherapy (IMRT) and stereotactic radiosurgery can improve outcomes for brain tumors by precisely targeting cancer cells while sparing healthy tissue. These methods are part of the treatment plan in the trial, suggesting potential effectiveness in combination with Dabrafenib and Trametinib.211121314
Who Is on the Research Team?
Rishi R Lulla
Principal Investigator
Children's Oncology Group
Are You a Good Fit for This Trial?
This trial is for children and young adults aged between 1 to 21 years with newly-diagnosed high-grade glioma that has a specific genetic change (BRAF V600 mutation). They must not have had any previous tumor-directed therapy other than surgery or corticosteroids, should be in good health otherwise, and able to follow the study procedures. Pregnant or breastfeeding females are ineligible, as well as those with certain medical conditions like uncontrolled heart disease.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Radiation Therapy
Patients undergo standardized local radiation therapy 5 days a week (Monday-Friday) for 6-7 weeks
Treatment
Patients receive dabrafenib mesylate orally twice daily and trametinib dimethyl sulfoxide once daily on days 1-28 of each cycle. Treatment repeats every 28 days for up to 24 cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment, with MRI and other assessments
What Are the Treatments Tested in This Trial?
Interventions
- Dabrafenib, Trametinib
- Radiation Therapy
Radiation Therapy is already approved in European Union, United States, Canada, Japan, China, Switzerland for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor